Serum S100B Represents a New Biomarker for Mood Disorders

E-ISSN： 1873-5592|14|11|1237-1248

ISSN： 1389-4501

Source： Current Drug Targets, Vol.14, Iss.11, 2013-10, pp. : 1237-1248

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of a 4-protein serum biomarker panel—biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)—for the detection of esophageal adenocarcinoma

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3902-3913

Blackwell Publishing

Access to resources Recommend Favorite

Women’s issues in mood disorders

By Goodnick P.J. Chaudry T. Artadi J. Arcey S.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 5, 2000-07 ,pp. : 903-916

Informa Healthcare

Access to resources Recommend Favorite

New Therapeutic Strategy for Mood Disorders

Current Medicinal Chemistry, Vol. 18, Iss. 28, 2011-10 ,pp. : 4284-4298

Bentham Science Publishers

Access to resources Recommend Favorite

Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases

Current Medicinal Chemistry, Vol. 23, Iss. 15, 2016-05 ,pp. : 1571-1596

Bentham Science Publishers

Access to resources Recommend Favorite

Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study

By Machado-Vieira R. Lara D.R. Portela L.V.C. Goncalves C.A. Soares J.C. Kapczinski F. Souza D.O.

European Neuropsychopharmacology, Vol. 12, Iss. 3, 2002-06 ,pp. : 269-272

Elsevier

Access to resources Recommend Favorite